Teligent, Inc.

Teligent, Inc. operates as a pharmaceutical preparations specialist focused on developing and marketing sterile injectable products and advanced drug delivery systems that serve hospitals, ambulatory care centers, and physician office practices across the United States; as a privately held entity within the broader Pharmaceutical Preparations SIC environment, it emphasizes bridging therapy gaps with generics and formulary-friendly alternatives while navigating FDA oversight and a complex reimbursement landscape. The company’s manufacturing and quality control infrastructure supports both branded offerings and contract development activities, with business development geared toward health systems and specialty distributors that need reliable supply chains and compliance-ready documentation. Material risks include tight regulatory scrutiny on sterile drug manufacturing, supply interruptions, pricing pressure from group purchasing organizations, and the challenge of sustaining adequate capital to fund clinical bridging studies and facility upgrades; management keeps investors apprised through periodic disclosures, most recently the Form 10-Q filed in November 1999. CIK 352998 reflects its long-running reporting obligations, so view live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025